Study to Assessment the Efficacy and Safety of Joint TAC and Exemestane as Neoadjuvant Chemotherapy in the Postmenopausal Women With Operable Breast Cancer
The investigators select the postmenopausal patients with breast cancer who is confirmed by
core needle biopsy and at the clinical stage T2-4N0-2M0.Treat them with 4 cycles of TAC as
neoadjuvant chemotherapy (Docetaxel was 75mg/m2, the EPI 60mg/m2 and the CTX
600mg/m2,21day/cycle).At the same time give daily oral exemestane 25mg for 12 weeks.Then
assess the efficacy and safety of TAC and Exemestane.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
therapeutic assessment
therapeutic assessment
6 months
Yes
jin Zhang, Professor
Study Chair
Tianjin cancer hospital
China: Ministry of Health
TENBC
NCT01648608
January 2012
December 2013
Name | Location |
---|